Articles by Arnold Chan - Pharmaceutical Executive


Articles by Arnold Chan

Making the Link

Post-marketing safety studies have one big problem: They're too slow. That's why companies are turning increasingly to databases that link prescribing data with patient outcomes.
May 1, 2006

The Zelnorm study was conducted for $1,000 per patient, a fraction of the price of clinical trials, which can cost $10,000 per patient or more.


Click here